EMERYVILLE, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Metagenomi Therapeutics, Inc. (Nasdaq: MGX) (the “Company”), an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients, today announced that Jian Irish, Ph.D., M.B.A., President and Chief Executive Officer of the Company, will participate in a fireside chat at the 46th Annual TD Cowen Healthcare Conference, being held in Boston, MA, on Monday, March 2, 2026 at 11:10 a.m. ET. The fires ...

Core Insights - The company has rebranded to Metagenomi Therapeutics, Inc. to reflect its strategic focus on advancing its lead program in hemophilia A and other promising technologies [1][2] - The MGX-001 program has shown curative factor VIII (FVIII) activity in non-human primates, with plans for IND/CTA submissions by the end of 2026 and a first-in-human study anticipated in 2027 [2][4] - The company expects its cash runway to extend through the fourth quarter of 2027, supporting its ongoing development efforts [2][12] Pipeline Advancements - MGX-001 has demonstrated durable FVIII activity over a 19-month study in non-human primates, with no off-target editing detected [6][10] - The company is exploring the potential of the MGX-001 system for treating other secreted protein deficiencies, including Antithrombin (AT-III) deficiency [7][10] - Recent strategic prioritization has strengthened the company's balance sheet and focused its pipeline on high-value therapeutic programs [12] Corporate Updates - The company appointed Jian Irish, Ph.D., M.B.A., as Chief Executive Officer, emphasizing a commitment to delivering curative genetic medicines [12] - Metagenomi Therapeutics aims to leverage its proprietary gene-editing technologies to expand its pipeline and address various genetic disorders [9][10]